Zeria Pharmaceutical Co., Ltd. (TYO:4559)
Japan · Delayed Price · Currency is JPY 2,040.00
-27.00 (-1.31%)
Jan 21, 2026, 3:30 PM JST
Zeria Pharmaceutical Cash Flow Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Net Income | 7,520 | 12,618 | 9,508 | 7,272 | 5,721 | 3,922 | Upgrade |
Depreciation & Amortization | 7,331 | 7,554 | 7,555 | 6,148 | 5,399 | 4,435 | Upgrade |
Loss (Gain) From Sale of Assets | - | - | - | - | - | 32 | Upgrade |
Loss (Gain) From Sale of Investments | 12 | 208 | -499 | -19 | -14 | -375 | Upgrade |
Loss (Gain) on Equity Investments | 276 | 276 | - | - | - | - | Upgrade |
Other Operating Activities | -2,242 | -1,039 | -906 | -530 | -864 | -512 | Upgrade |
Change in Accounts Receivable | -807 | -4,800 | -2,075 | -171 | -2,029 | 825 | Upgrade |
Change in Inventory | -4,462 | -1,647 | -863 | -150 | -542 | -753 | Upgrade |
Change in Accounts Payable | 1,190 | 567 | 1,052 | -207 | 284 | -40 | Upgrade |
Change in Other Net Operating Assets | -1,201 | -815 | -1,589 | 814 | 995 | -640 | Upgrade |
Operating Cash Flow | 7,617 | 12,922 | 12,183 | 13,157 | 8,950 | 6,894 | Upgrade |
Operating Cash Flow Growth | -52.14% | 6.07% | -7.40% | 47.01% | 29.82% | -4.92% | Upgrade |
Capital Expenditures | -1,968 | -1,429 | -2,900 | -2,400 | -1,064 | -734 | Upgrade |
Cash Acquisitions | - | - | -623 | - | - | -2,464 | Upgrade |
Sale (Purchase) of Intangibles | -1,435 | -1,304 | -998 | -257 | -356 | -15,398 | Upgrade |
Investment in Securities | 1,967 | 1,662 | 473 | 58 | -1,477 | 1,173 | Upgrade |
Other Investing Activities | 13 | 21 | 96 | 25 | 5 | -37 | Upgrade |
Investing Cash Flow | -1,423 | -1,050 | -3,952 | -2,574 | -2,892 | -17,460 | Upgrade |
Short-Term Debt Issued | - | - | - | 279 | - | 12,744 | Upgrade |
Long-Term Debt Issued | - | 3,273 | 500 | 500 | 16,158 | 4,500 | Upgrade |
Total Debt Issued | 2,273 | 3,273 | 500 | 779 | 16,158 | 17,244 | Upgrade |
Short-Term Debt Repaid | - | -143 | -560 | - | -13,241 | - | Upgrade |
Long-Term Debt Repaid | - | -8,515 | -5,778 | -5,628 | -3,388 | -3,122 | Upgrade |
Total Debt Repaid | -5,773 | -8,658 | -6,338 | -5,628 | -16,629 | -3,122 | Upgrade |
Net Debt Issued (Repaid) | -3,500 | -5,385 | -5,838 | -4,849 | -471 | 14,122 | Upgrade |
Repurchase of Common Stock | - | - | - | -673 | -2,603 | -1,154 | Upgrade |
Common Dividends Paid | -2,067 | -1,976 | -1,935 | -1,590 | -1,538 | -1,568 | Upgrade |
Other Financing Activities | -409 | -395 | -351 | -303 | -229 | -215 | Upgrade |
Financing Cash Flow | -5,976 | -7,756 | -8,124 | -7,415 | -4,841 | 11,185 | Upgrade |
Foreign Exchange Rate Adjustments | 143 | 749 | 2,402 | 1,346 | 564 | 169 | Upgrade |
Miscellaneous Cash Flow Adjustments | -1 | -2 | 1 | - | 128 | - | Upgrade |
Net Cash Flow | 360 | 4,863 | 2,510 | 4,514 | 1,909 | 788 | Upgrade |
Free Cash Flow | 5,649 | 11,493 | 9,283 | 10,757 | 7,886 | 6,160 | Upgrade |
Free Cash Flow Growth | -58.69% | 23.81% | -13.70% | 36.41% | 28.02% | -7.07% | Upgrade |
Free Cash Flow Margin | 6.66% | 13.16% | 12.26% | 15.73% | 13.25% | 11.11% | Upgrade |
Free Cash Flow Per Share | 128.16 | 260.73 | 210.59 | 243.52 | 174.71 | 133.70 | Upgrade |
Cash Interest Paid | 482 | 492 | 446 | 300 | 304 | 223 | Upgrade |
Cash Income Tax Paid | 2,220 | 1,001 | 915 | 564 | 874 | 526 | Upgrade |
Levered Free Cash Flow | 2,655 | 7,627 | 7,850 | 8,807 | 6,071 | -12,962 | Upgrade |
Unlevered Free Cash Flow | 2,943 | 7,910 | 8,136 | 9,017 | 6,268 | -12,813 | Upgrade |
Change in Working Capital | -5,280 | -6,695 | -3,475 | 286 | -1,292 | -608 | Upgrade |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.